Advertisement

Topics

DalCor’s Phase 3 cardiovascular trial, dal-GenE, exceeds targeted enrollment schedule

11:35 EDT 16 Mar 2017 | Biotechnology Focus

LONDON, UK & MONTREAL, QC — DalCor Pharmaceuticals reports it is ahead of its enrollment schedule with the randomization of over 1,000 of the planned 5,000 patients that will take part in the company’s Phase 3 “dal-GenEclinical trial. “We are pleased and gratified that recruitment goals are ahead of schedule,” said Dr. Jean-Claude Tardif, director [&hellip

Original Article: DalCor’s Phase 3 cardiovascular trial, dal-GenE, exceeds targeted enrollment schedule

NEXT ARTICLE

More From BioPortfolio on "DalCor’s Phase 3 cardiovascular trial, dal-GenE, exceeds targeted enrollment schedule"

Quick Search
Advertisement
 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...